

**Supplemental Table 2:** Change in prevalence of optical coherence tomography (OCT) features in patients with Best vitelliform macular dystrophy over time.

	Baseline	Follow-up	p-value
<b>Number of Eyes</b>	65		-
<b>Follow-up Period [Years] (mean, median, range)</b>	5.1, 5, 1 to 11		-
<b>Age [Years] (mean, median, range)</b>	40.1, 42.0, 4 to 84	45.1, 50.0, 8 to 89	0.12
<b>LogMAR BCVA (mean, median, range)</b>	0.34, 0.3, -0.12 to 1.0	0.27, 0.20, -0.52 to 0.90	0.18
<b>% Eyes with BCVA <math>\geq</math> 20/50</b>	60	65	0.33
<b>CST [<math>\mu</math>m] (mean, median, range)</b>	359.7, 329, 177 to 627	340, 321, 142 to 629	0.17
<b><u>Feature Rate (%)</u></b>			
<b>Pre-VL</b>	10.8	3.1	0.23
<b>Solid VL</b>	10.8	15.4	0.33
<b>SRF</b>	7.7	7.4	0.38
<b>Pillar</b>	21.5	21.5	0.50
<b>FCE</b>	13.9	26.2	0.11
<b>IRF</b>	16.9	16.9	0.50
<b>Atrophy</b>	9.2	15.4	0.55
<b>CNV</b>	15.4	18.5	0.38

Abbreviations: BCVA: best corrected visual acuity; Pre-VL: pre-vitelliform; VL: vitelliform; SRF: subretinal fluid; FCE: focal choroidal excavation; IRF: intraretinal fluid; VA: visual acuity; CST: central subfield thickness; CNV: choroidal neovascularization. P-value <0.05 considered statistically significant.